Jump Financial LLC Has $2.22 Million Stock Holdings in Omnicell, Inc. $OMCL

Jump Financial LLC boosted its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 63.4% in the first quarter, according to its most recent filing with the SEC. The firm owned 63,627 shares of the company’s stock after acquiring an additional 24,699 shares during the period. Jump Financial LLC owned 0.14% of Omnicell worth $2,224,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. Victory Capital Management Inc. grew its holdings in Omnicell by 10.1% during the 1st quarter. Victory Capital Management Inc. now owns 1,680,347 shares of the company’s stock worth $58,745,000 after acquiring an additional 154,038 shares during the period. Dimensional Fund Advisors LP grew its holdings in Omnicell by 31.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company’s stock worth $73,127,000 after acquiring an additional 394,820 shares during the period. Lazard Asset Management LLC grew its holdings in Omnicell by 81.6% during the 4th quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company’s stock worth $73,093,000 after acquiring an additional 737,536 shares during the period. ArrowMark Colorado Holdings LLC grew its holdings in Omnicell by 4.9% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 1,196,990 shares of the company’s stock worth $53,290,000 after acquiring an additional 56,117 shares during the period. Finally, Toronto Dominion Bank acquired a new stake in Omnicell during the 4th quarter worth $30,637,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Trading Up 1.6%

OMCL opened at $33.23 on Thursday. The stock has a market capitalization of $1.53 billion, a P/E ratio of 66.46, a P/E/G ratio of 7.15 and a beta of 0.78. Omnicell, Inc. has a 12 month low of $22.66 and a 12 month high of $55.74. The firm’s fifty day simple moving average is $29.88 and its 200 day simple moving average is $31.75. The company has a current ratio of 1.42, a quick ratio of 1.24 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, July 31st. The company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.30 by $0.15. The business had revenue of $290.56 million for the quarter, compared to analysts’ expectations of $275.57 million. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The firm’s revenue was up 5.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.51 EPS. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. As a group, research analysts anticipate that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on OMCL. Wells Fargo & Company boosted their price target on shares of Omnicell from $37.00 to $40.00 and gave the company an “overweight” rating in a report on Monday, July 21st. Piper Sandler decreased their price target on shares of Omnicell from $57.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 11th. Benchmark decreased their price target on shares of Omnicell from $62.00 to $40.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. Wall Street Zen lowered shares of Omnicell from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 9th. Finally, Bank of America boosted their price target on shares of Omnicell from $30.00 to $34.00 and gave the company a “neutral” rating in a report on Friday, May 23rd. Four research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $46.71.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.